[go: up one dir, main page]

DE60015516D1 - Verwendung von makroliden zur behandlung von trockenen augen - Google Patents

Verwendung von makroliden zur behandlung von trockenen augen

Info

Publication number
DE60015516D1
DE60015516D1 DE60015516T DE60015516T DE60015516D1 DE 60015516 D1 DE60015516 D1 DE 60015516D1 DE 60015516 T DE60015516 T DE 60015516T DE 60015516 T DE60015516 T DE 60015516T DE 60015516 D1 DE60015516 D1 DE 60015516D1
Authority
DE
Germany
Prior art keywords
macrolids
dry eyes
treat dry
treat
eyes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60015516T
Other languages
English (en)
Other versions
DE60015516T2 (de
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
R Tech Ueno Ltd
Original Assignee
Sucampo GmbH
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60015516(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo GmbH, R Tech Ueno Ltd filed Critical Sucampo GmbH
Publication of DE60015516D1 publication Critical patent/DE60015516D1/de
Application granted granted Critical
Publication of DE60015516T2 publication Critical patent/DE60015516T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
DE60015516T 1999-04-30 2000-04-26 Verwendung von makroliden zur behandlung von trockenen augen Expired - Lifetime DE60015516T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13200999P 1999-04-30 1999-04-30
US132009P 1999-04-30
PCT/JP2000/002756 WO2000066122A1 (en) 1999-04-30 2000-04-26 Use of macrolide compounds for the treatment of dry eye

Publications (2)

Publication Number Publication Date
DE60015516D1 true DE60015516D1 (de) 2004-12-09
DE60015516T2 DE60015516T2 (de) 2005-12-01

Family

ID=22452015

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60015516T Expired - Lifetime DE60015516T2 (de) 1999-04-30 2000-04-26 Verwendung von makroliden zur behandlung von trockenen augen

Country Status (23)

Country Link
EP (1) EP1173177B2 (de)
JP (2) JP5036934B2 (de)
KR (1) KR20020015316A (de)
CN (1) CN1190194C (de)
AR (1) AR023807A1 (de)
AT (1) ATE281167T1 (de)
AU (1) AU777915B2 (de)
BR (1) BR0011225A (de)
CA (1) CA2372448A1 (de)
CZ (1) CZ20013769A3 (de)
DE (1) DE60015516T2 (de)
ES (1) ES2232439T3 (de)
HK (2) HK1043321B (de)
HU (1) HUP0200864A3 (de)
IL (1) IL146162A0 (de)
MX (1) MXPA01010988A (de)
NO (1) NO20015288L (de)
NZ (1) NZ515339A (de)
PT (1) PT1173177E (de)
TR (1) TR200103119T2 (de)
TW (1) TWI230066B (de)
WO (1) WO2000066122A1 (de)
ZA (1) ZA200108905B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01010988A (es) * 1999-04-30 2004-04-21 Sucampo Ag Uso de un compuesto macrolido para el tratamiento del ojo seco.
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1406700A1 (de) 2001-07-06 2004-04-14 Sucampo AG Zurbereitung zur topischen anwendung enthaltend einen interleukin-2 inhibitor und eine antimikrobielle substanz
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
CN1674896A (zh) * 2002-08-09 2005-09-28 苏坎波制药有限公司 含有fk506衍生物的药物组合物及其用于治疗过敏性疾病的用途
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20040198763A1 (en) * 2003-01-16 2004-10-07 Sucampo Ag Method of treating dry eye with a macrolide compound
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CN102144961A (zh) 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
WO2005032534A1 (ja) 2003-10-06 2005-04-14 Ophtecs Corporation 涙液異常の治療のための眼科用組成物
BRPI0607606B1 (pt) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
AU2006270041B2 (en) 2005-07-18 2011-08-18 Minu, Llc Enhanced ocular neuroprotection/neurostimulation
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
EP2335735A1 (de) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmazeutische Zusammensetzung zur Behandlung von trockenem Auge
KR20200069261A (ko) * 2017-05-30 2020-06-16 엑시모어 엘티디. 항생제 마크로라이드를 전달하는 안구건조증을 치료하기 위한 조성물 및 방법
WO2019060696A1 (en) 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
JP2022516099A (ja) 2018-12-27 2022-02-24 サーフィス オフサルミクス，インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0406791B1 (de) * 1989-07-05 1995-02-01 Fujisawa Pharmaceutical Co., Ltd. Wässriges flüssiges Mittel zur äusserlichen Anwendung
ES2154262T3 (es) * 1991-04-26 2001-04-01 Fujisawa Pharmaceutical Co Uso de compuestos macrolidos para enfermedades oculares.
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
EP1067926A2 (de) * 1998-04-06 2001-01-17 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive imidazolverbindungen und deren kombinationspräparate mit tacrolimus oder cyclosporinen
JP3732525B2 (ja) * 1998-04-27 2006-01-05 アステラス製薬株式会社 医薬組成物
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
MXPA01010988A (es) * 1999-04-30 2004-04-21 Sucampo Ag Uso de un compuesto macrolido para el tratamiento del ojo seco.

Also Published As

Publication number Publication date
NO20015288D0 (no) 2001-10-29
JP2002543132A (ja) 2002-12-17
ZA200108905B (en) 2002-12-24
AR023807A1 (es) 2002-09-04
CN1353608A (zh) 2002-06-12
EP1173177A1 (de) 2002-01-23
PT1173177E (pt) 2005-03-31
HK1043321B (en) 2005-07-15
JP5036934B2 (ja) 2012-09-26
EP1173177B1 (de) 2004-11-03
CA2372448A1 (en) 2000-11-09
BR0011225A (pt) 2002-03-19
JP2012116857A (ja) 2012-06-21
KR20020015316A (ko) 2002-02-27
IL146162A0 (en) 2002-07-25
NZ515339A (en) 2004-02-27
AU777915B2 (en) 2004-11-04
CZ20013769A3 (cs) 2002-03-13
TR200103119T2 (tr) 2002-04-22
HUP0200864A3 (en) 2004-07-28
ES2232439T3 (es) 2005-06-01
EP1173177B2 (de) 2014-03-05
ATE281167T1 (de) 2004-11-15
HK1046099A1 (zh) 2002-12-27
HK1043321A1 (en) 2002-09-13
TWI230066B (en) 2005-04-01
CN1190194C (zh) 2005-02-23
AU4142900A (en) 2000-11-17
NO20015288L (no) 2001-10-29
MXPA01010988A (es) 2004-04-21
WO2000066122A1 (en) 2000-11-09
HUP0200864A2 (hu) 2002-07-29
DE60015516T2 (de) 2005-12-01

Similar Documents

Publication Publication Date Title
DE60015516D1 (de) Verwendung von makroliden zur behandlung von trockenen augen
ATE419856T1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69903543D1 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE475427T1 (de) Verwendung von botulinum toxin zur behandlung von eingweideschmerzen
DE69926385D1 (de) Behandlung von geweben
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ATE353218T1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
DE69813935D1 (de) Verwendung von Retinoiden zur Induzierung von Hautpigmentierung
DE60023816D1 (de) Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungs-Erscheinungen
DE60137929D1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
ATE338552T1 (de) Verwendungen von et743 zur behandlung von krebs
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69702862D1 (de) Verwendung von sulfatierten polysacchariden zur behandlung einer chronischer verletzung
EP1117431A4 (de) Behandlung von acidose
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
EP1239851A4 (de) Behandlung von hyperproliferativen erkrankungen
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
ATE317261T1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE190486T1 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
ATE267608T1 (de) Verwendung von fsh zur behandlung von infertilität

Legal Events

Date Code Title Description
8363 Opposition against the patent